Statin use and the risk of developing diabetes: a network meta‐analysis
@article{Thakker2016StatinUA, title={Statin use and the risk of developing diabetes: a network meta‐analysis}, author={Divyesh Thakker and Sunita R. Nair and Amit Pagada and Vinayak Sudhir Jamdade and Anuradha Malik}, journal={Pharmacoepidemiology and Drug Safety}, year={2016}, volume={25}, pages={1131 - 1149} }
Randomized controlled trials have shown mixed findings regarding the association of statins and diabetes. This systematic literature review and network meta‐analysis (NMA) was performed to update evidence on this association to possibly assist clinicians in making more informed treatment choices.
81 Citations
Statin users have an elevated risk of dysglycemia and new‐onset‐diabetes
- MedicineDiabetes/metabolism research and reviews
- 2019
This work sought to understand the risk of dysglycemia and NOD for a cohort of individuals that reflect real‐world physician prescribing patterns and identify patients at risk of new‐onset‐diabetes development.
Associations of statin use with glycaemic traits and incident type 2 diabetes
- Biology, MedicineBritish journal of clinical pharmacology
- 2019
This study aimed to investigate the association of statin use with glycaemic traits and incident type 2 diabetes.
Statins are associated with new onset type 2 diabetes mellitus (T2DM) in Medicare patients ≥65 years
- MedicineDiabetes/metabolism research and reviews
- 2020
To evaluate the association of statins and co‐morbidities with new onset type 2 diabetes mellitus (T2DM) in patients 65 years and older, a large number of patients with T2DM are enrolled.
Statin use and risk of new-onset diabetes: A meta-analysis of observational studies.
- MedicineNutrition, metabolism, and cardiovascular diseases : NMCD
- 2017
Statins and diabetes: focus on pitavastatin
- Medicine, Biology
- 2020
Particular attention is paid to the place of pitavastatin, due to its low diabetogenicity and minimal risk of drug interactions, as well as the need of taking into consideration the risk factors of diabetes and the preventive measures in patients receiving statin therapy.
The Challenge: Finding the Most Appropriate Statin and Dose for Each Patient.
- Medicine, PsychologyThe Journal of family practice
- 2021
The nocebo effect is a common reason for perceived statin intolerance and several strategies are available that can enable continuation of statin therapy in patients who are truly statin-intolerant.
Statin use and risk of developing diabetes: results from the Diabetes Prevention Program
- MedicineBMJ Open Diabetes Research & Care
- 2017
In this population at high risk for diabetes, the authors observed significantly higher rates of diabetes with statin therapy in all three treatment groups, and the effect of statins to increase diabetes risk appears to extend to populations at highrisk for diabetes.
Statin use and safety concerns: an overview of the past, present, and the future
- BiologyExpert opinion on drug safety
- 2020
The most common adverse effects of statins are described, available evidence is examined and the role of ethnicity, lipophilicity and other biological factors that could mediate and/or influence the relationship are highlighted.
Association between statin treatment and new-onset diabetes mellitus: a population based case–control study
- Medicine, PsychologyDiabetology & Metabolic Syndrome
- 2019
The risk of NODM was not associated with an increase in the cumulative duration of statin use or with non-recent use, and only recent short-term use of cholesterol-lowering statin was associated with a increased risk ofNODM.
Diabetes Caused by Statin Use: A Review
- Medicine, Biology
- 2020
Many studies have concluded that Pitavastatin and pravastatinom do not affect glycemic control and may be a beneficial treatment option in patients with, or at risk for, type 2 diabetes.
References
SHOWING 1-10 OF 59 REFERENCES
Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis
- MedicineDiabetes Care
- 2009
Although statin therapy greatly lowers vascular risk, including among those with and at risk for diabetes, the relationship ofstatin therapy to incident diabetes remains uncertain and future statin trials should be designed to formally address this issue.
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
- MedicineThe Lancet
- 2010
Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus.
- MedicineThe American journal of cardiology
- 2013
Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis.
- Medicine, BiologyQJM : monthly journal of the Association of Physicians
- 2012
A meta-analysis and indirect comparisons employed to identify differing risk effects across statins found that atorvastatin significantly elevated AST levels compared to pravastatin and simvASTatin significantly increased CK levels when compared to rosuvastsatin.
Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study
- MedicineBMJ : British Medical Journal
- 2014
Among people with impaired glucose tolerance and other cardiovascular risk factors and with serial glucose measurements, diuretics and statins were associated with an increased risk of new onset diabetes, whereas the effect of β blockers was non-significant.
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.
- MedicineJAMA
- 2011
In a pooled analysis of data from 5 statin trials, intensive-dose statin therapy was associated with an increased risk of new-onset diabetes compared with moderate-dosestatin therapy.
Comparative Tolerability and Harms of Individual Statins: A Study-Level Network Meta-Analysis of 246 955 Participants From 135 Randomized, Controlled Trials
- MedicineCirculation. Cardiovascular quality and outcomes
- 2013
As a class, adverse events associated with statin therapy are not common but do result in a higher odds of diabetes mellitus and among individual statins, simvastatin and pravastatin seem safer and more tolerable than other statins.
Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial
- MedicineThe Lancet
- 2006
Management of cardiovascular risk: the importance of meeting lipid targets.
- MedicineThe American journal of cardiology
- 2012